{"id":"77e3250643e2","type":"article","url":"https://hartvaat.nl/2018/10/18/omega-3-vetzuursupplementen-bij-diabetes-nejm-ascend-omega-3/","title":"Omega-3 vetzuursupplementen bij diabetes: NEJM ASCEND omega-3","title_en":"Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":["select-trial","soul-trial"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMoa1804989","source_url":"https://doi.org/10.1056/NEJMoa1804989","authors":["Louise Bowman","Marion Mafham","Karl Wallendszus","Will Stevens","Georgina Buck","Jill Barton","Kevin Murphy","Theingi Aung","Richard Haynes","Jolyon Cox","Aleksandra Murawska","Allen Young","Michael Lay","Fang Chen","Emily Sammons","Emma Waters","Amanda Adler","Jonathan Bodansky","Andrew Farmer","Roger McPherson","Andrew Neil","David Simpson","Richard Peto","Colin Baigent","Rory Collins","Sarah Parish","Jane Armitage"],"significance":8,"published":"2018-10-18","source_date":"2018-10-18","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ezetimib/","https://hartvaat.nl/kennis/lipiden/bempedoïnezuur/"],"congress":"","summary_en":"The omega-3 component of the ASCEND trial found no significant cardiovascular benefit of n-3 fatty acid supplementation in patients with diabetes over a median of 7.4 years. The result added to the evidence against routine fish oil supplementation for cardiovascular prevention.","created":"2026-07-03T10:27:33Z","updated":"2026-07-03T13:26:47Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"NEJM ASCEND omega-3 component die geen significant voordeel aantoonde van omega-3 vetzuursupplementen bij diabetespatiënten. Definitieve negatieve trial.","abstract_original":"BACKGROUND: Increased intake of n-3 fatty acids has been associated with a reduced risk of cardiovascular disease in observational studies, but this finding has not been confirmed in randomized trials. It remains unclear whether n-3 (also called omega-3) fatty acid supplementation has cardiovascular benefit in patients with diabetes mellitus. METHODS: We randomly assigned 15,480 patients with diabetes but without evidence of atherosclerotic cardiovascular disease to receive 1-g capsules containing either n-3 fatty acids (fatty acid group) or matching placebo (olive oil) daily. The primary outcome was a first serious vascular event (i.e., nonfatal myocardial infarction or stroke, transient ischemic attack, or vascular death, excluding confirmed intracranial hemorrhage). The secondary outcome was a first serious vascular event or any arterial revascularization. RESULTS: During a mean follow-up of 7.4 years (adherence rate, 76%), a serious vascular event occurred in 689 patients (8.9%) in the fatty acid group and in 712 (9.2%) in the placebo group (rate ratio, 0.97; 95% confidence interval [CI], 0.87 to 1.08; P=0.55). The composite outcome of a serious vascular event or revascularization occurred in 882 patients (11.4%) and 887 patients (11.5%), respectively (rate ratio, 1.00; 95% CI, 0.91 to 1.09). Death from any cause occurred in 752 patients (9.7%) in the fatty acid group and in 788 (10.2%) in the placebo group (rate ratio, 0.95; 95% CI, 0.86 to 1.05). There were no significant between-group differences in the rates of nonfatal serious adverse events. CONCLUSIONS: Among patients with diabetes without evidence of cardiovascular disease, there was no significant difference in the risk of serious vascular events between those who were assigned to receive n-3 fatty acid supplementation and those who were assigned to receive placebo. (Funded by the British Heart Foundation and others; Current Controlled Trials number, ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .)."}